Kezar Life Sciences Inc at Jefferies Healthcare Conference Transcript
My name is Maury Raycroft, and I'm one of the biotech analysts at Jefferies. And I'd like to welcome the Kezar team with me today, and we're going to do a fireside chat discussion. Maybe to start off if you want to provide a one-minute intro to Kezar.
Yeah, hi, everybody. Thanks for joining us today. My name is John Fowler. I'm Co-Founder and CEO of Kezar. Founded the company in 2015 and actually met Maury in 2018. We've been working together for five years now.
We're based in the San Francisco Bay area, went public in 2018, and we actually have two drugs in the clinic at this time. Our lead asset is a small molecule called zetomipzomib -- we'll refer to it as zeto today -- is a selective immunoproteasome inhibitor. We have seen some amazing results to date, treating patients with both lupus and lupus nephritis, and we're currently enrolling a Phase 2b in lupus nephritis and also a Phase 2 in autoimmune hepatitis.
Our other clinical asset is a
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
